Title:
3D Cell Culture
Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts (4th Edition), 2022-2035.
Example Highlights:
Overview:
Animal testing has been the most common method in various experimental studies in biomedical research, given their resemblance to humans in terms of genetics, anatomy, and physiology. Specifically, mice genome has 80% similarity with humans, which makes them excellent models for various research purposes. However, the use of animals in scientific research is associated with several ethical concerns, which led to the establishment of the principle of 3Rs- Replacement, Reduction and Refinement, to address the ethical concerns related to animal welfare and limit the use of animals in scientific research. As of 2018, this initiative led to 50% reduction in the use of animals as compared to the statistics noted in 1985. Further, the process of animal breeding / housing for scientific purposes is also associated with high costs and requires skilled labor. Moreover, it has been demonstrated that animal cell cultures are unable to accurately mimic the natural (in vivo) microenvironment as the cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. These concerns have necessitated a transition from animal-based testing to the use of 3-dimensional (3D) cell culture models. Over time, advances in biotechnology and materials science have enabled the development of a variety of 3D cell culture systems in order to drive research across different application areas, including cancer research, drug discovery, tissue engineering and others.
At present, more than 140 companies offer 3D cell culture systems in a variety of formats, including scaffold-based products, scaffold-free products and 3D bioreactors. These systems have demonstrated to be capable of more accurately simulating the natural tissue microenvironment, offer increased cell-to-cell and cell-to-ECM interactions, more accurate evaluation of drug toxicity and cellular responses, and co-cultuirng of multiple cell types together. Moreover, there are certain complex 3D cell culture models that can even replace animal models exhibiting reproducible results and thereby, serving as better in vivo models across multiple application areas. Given the various benefits of such systems, the field has garnered the attention of various venture capital firms and strategic investors that have been providing financial support to drive research efforts focused on exploring different formats of 3D cell culture systems, including organoids and organ-on-chips across multiple application areas. Moreover, there has been an increase in scientific literature on 3D cell culture systems and collaborations for 3D bioreactors and cell culture products. Given the ongoing innovation in this field, and the paradigm shift from 2D cell culture systems and animal testing to 3D cell culture models, the market is likely to witness a significant growth in the foreseen future.
Scope of the Report:
The "3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (4th Edition), 2022-2035" report features an extensive study of the current landscape, offering an informed opinion on the likely evolution of the market in the mid to long term. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this domain. Amongst other elements, the report includes:
- A detailed discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors.
- An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.
- An overview of the current market landscape of companies offering various 3D cell culture systems, including information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.
- A detailed assessment of the overall landscape of scaffold based products, along with analyses based on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of scaffold (human based, chemical based, animal based, plant based, and polymer based), and fabrication material used. In addition, it presents details of the companies involved in the development of scaffold based products, providing information on their year of establishment, company size, and location of headquarters.
- A detailed assessment of the overall landscape of scaffold free products, along with analyses based on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), type of material (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies involved in the development of scaffold free products, providing information on their year of establishment, company size, and location of headquarters.
- A detailed assessment of the overall landscape of 3D bioreactors, along with analyses based on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), status of development (under development, developed and not commercialized, and commercialized), typical working volume, scale of operation (lab scale, pre-clinical / clinical scale and commercial scale), type of manufacturing process (batch-continuous, fed-batch and continuous), type of cell culture system (mammalian cell, insect cell, microbial cell, and plant cell), type of molecule processed (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy and gene therapy), and application area (drug discovery / toxicity testing, stem cell research, regenerative medicine / tissue engineering and cancer research). In addition, it presents details of the companies involved in the development of 3D bioreactors, providing information on their year of establishment, company size, and location of headquarters.
- A detailed review of the key application areas (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.
- Elaborate profiles of prominent players offering Scaffold-based, Scaffold-free cell culture systems and 3D bioreactors (shortlisted based on the number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile includes a brief overview of the company, financial / funding information (if available), details on its product portfolio, recent developments, and an informed future outlook.
- An analysis of the investments made in the period between 2016-2022, including instances of seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.
- An analysis of the various partnerships related to 3D cell culture products, which have been established since 2015, based on several parameters, such as year of agreement, type of partnership (product development and commercialization agreements, product integration and utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.
- An in-depth analysis of over 6,400 patents that have been filed / granted for 3D cell culture products, between 2016-2021, based on parameters, such as type of patent, publication year, issuing authority involved, CPC symbols, type of applicant, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis.
- An analysis of more than 3,800 peer-reviewed scientific articles related to 3D cell culture and its technologies, published since 2019, based on several parameters, such as year of publication, emerging focus areas, most popular authors, and most popular journals (in terms of number of articles published in the given time period and journal impact factor), top publisher and type of funding institute.
- An in-depth competitiveness analysis of 3D bioreactors, taking into consideration the supplier power (based on the year of establishment of the 3D bioreactors developer) and key features of bioreactors, such as scale of operation (lab scale, pre-clinical / clinical scale and commercial scale), type of molecule supported (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy and gene therapy), type of cell culture supported (mammalian cell, insect cell, microbial cell, and plant cell) and application area (drug discovery / toxicity testing, stem cell research, regenerative medicine/tissue engineering and cancer research).
- A case study on the 3D cell culture products for organoids and organ-on-chips, along with analysis based on parameters, such as status of development, and area of applications. In addition, it presents details of the developer companies, along with information on their year of establishment, company size, and location of headquarters.
- Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products, emphasized on the focus area of their company, type of 3D cell culture products offered, development status of the product(s), method of fabrication used, source of 3D cultured cells, application area of product(s), type of service(s) offered, and present and future market opportunity.
One of the key objectives of the report was to identify the primary growth drivers and estimate the potential future size of the 3D cell culture market. Based on various parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have developed informed estimates on the likely evolution of the 3D cell culture systems market, for the period 2022-2035. Our year-wise projections of the current and forecasted opportunity have further been segmented across 3D cell culture format (scaffold based systems, scaffold free systems, and 3D bioreactors), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), purpose (research use and therapeutic use), key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world), and leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:
- Brigitte Angres (Co-founder, Cellendes)
- Bill Anderson (President and CEO, Synthecon)
- Anonymous (President and CEO, Anonymous)
- Anonymous (Co-founder and Vice President, Anonymous)
- Scott Brush (Vice President, BRTI Life Sciences)
- Malcolm Wilkinson (Managing Director, Kirkstall)
- Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)
- Tanya Yankelevich (Director, Xylyx Bio)
- Jens Kelm (Chief Scientific Officer, InSphero)
- Walter Tinganelli (Group Leader, GSI)
- Darlene Thieken (Project Manager, Nanofiber Solutions)
- Andrea Picon (Director, Business Development, FlexCell International)
- Frank Junker (Chief Business Officer, InSphero)
- Mohammed Mamunur Rahman (Manager, Business Development, MBL International)
Key Questions Answered:
- Who are the leading industry players engaged in the development of 3D cell culture products?
- Which are the most popular 3D cell culture products?
- Which are the different application areas for which 3D cell culture products are being developed?
- What are the key factors that are likely to influence the evolution of 3D cell culture systems market?
- What is the trend of capital investments in the 3D cell culture systems market?
- Which partnership models are commonly adopted by stakeholders in 3D cell culture market?
- How is the current and future opportunity likely to be distributed across key market segments?
- What are the anticipated future trends related to 3D cell culture systems market?
Chapter Outlines:
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state and the likely evolution of the 3D cell culture systems market in the mid to long term.
Chapter 3 provides a general introduction to 3D cell culture systems. The chapter presents information on the different types of cell cultures, methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.
Chapter 4 provides an overview of the classification of 3D culture systems, namely scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also provides insights on the underlying concepts, advantages and disadvantages of the aforementioned products.
Chapter 5 presents summary of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. In addition, the chapter provides information on the working principle, benefits and limitations associated with each method used for fabricating scaffolds. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.
Chapter 6 includes information on around 140 industry players offering various 3D cell culture products. It features detailed analyses of developers, based on year of establishment, company size, location of headquarters, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides different insightful representations, which include [A] a heat map representation, illustrating the distribution of developers, based on 3D cell culture format and location of headquarters, [B] tree map representation, presenting the distribution of developers, based on type of product and company size, and [C] world map representation, highlighting the regional distribution of headquarters of the developer companies.
Chapter 7 presents information on around 200 scaffold based products that are either commercialized or under development. It features detailed analysis of these products based on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized) type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of scaffold (human based, chemical based, animal based, plant based, and polymer based), and fabrication material. In addition, it presents details of the companies involved in the development of scaffold based products, providing information on their year of establishment, company size, and location of headquarters.
Chapter 8 presents information on around 40 scaffold free products that are either commercialized or under development. It features detailed analysis of these products based on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), type of material (human based, animal based, plant based and polymer based), and material used of fabrication. In addition, it presents details of the companies involved in the development of scaffold free products, providing information on their year of establishment, company size, and location of headquarters.
Chapter 9 presents information on around 90 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), status of development (under development, developed and not commercialized, and commercialized), typical working volume, scale of operation (lab scale, pre-clinical / clinical scale and commercial scale), type of manufacturing process (batch-continuous, fed-batch and continuous), type of cell culture system (mammalian cell, insect cell, microbial cell, and plant cell), type of molecule processed (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy and gene therapy), and application area (drug discovery / toxicity testing, stem cell research, regenerative medicine / tissue engineering and cancer research). In addition, it presents details of the companies involved in the development of 3D bioreactors, providing information on their year of establishment, company size, and location of headquarters.
Chapter 10 presents information on the key application areas (cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.
Chapter 11 features elaborate profiles of prominent players engaged in the development of scaffold based products (offering at least five hydrogel / ECM products). Each company profile includes a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook.
Chapter 12 features elaborate profiles of prominent players engaged in the development of scaffold free products (offering at least three scaffold free cell culture products). Each company profile includes a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook.
Chapter 13 features elaborate profiles of prominent players that engaged in the development of 3D bioreactors (offering at least two bioreactors). Each company profile includes a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook.
Chapter 14 features an analysis of the investments made in the period between 2016-2022, including instances of seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.
Chapter 15 features an analysis of the various partnerships related to 3D cell culture products, that have been established since 2015, based on several parameters, such as year of agreement, type of partnership (product development and commercialization agreements, product integration and utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.
Chapter 16 provides an in-depth analysis of over 6,400 patents that have been filed / granted for 3D cell culture products, between 2016-2021, based on parameters, such as type of patent, publication year, issuing authority involved, CPC symbols, type of applicant, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis.
Chapter 17 features an analysis of more than 3,800 peer-reviewed scientific articles related to 3D cell culture and its technologies, published since 2019, based on several parameters, based on several parameters, such as year of publication, emerging focus areas, most popular authors, and most popular journals (in terms of number of articles published in the given time period and journal impact factor), top publisher and type of funding institute.
Chapter 18 features an insightful competitiveness analysis of 3D bioreactors, taking into consideration the supplier power (based on the year of establishment of the 3D bioreactors developer) and key features of bioreactors, such as scale of operation (lab scale, pre-clinical/clinical scale and commercial scale), type of molecule supported (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy and gene therapy), type of cell culture supported (mammalian cell, insect cell, microbial cell, and plant cell) and application area (drug discovery / toxicity testing, stem cell research, regenerative medicine / tissue engineering and cancer research).
Chapter 19 is a case study providing an overview on the current market landscape of 3D cell culture products for organoids and organ-on-chips, along with analysis based on parameters, such as development status, and area of application. In addition, it presents details of the developer companies, along with information on their year of establishment, company size, and location of headquarters.
Chapter 20 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, till 2035. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture format (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world), and [F] leading product developers.
Chapter 21 presents insights from the survey conducted for this study. We contacted over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.
Chapter 22 is a summary of the overall report. It presents a list of key takeaways and our independent opinions on the current market scenario.
Chapter 23 is a collection of interview transcripts of the discussions held with various stakeholders in the industry. We have presented details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions), Andrea Picon (Director, Business Development, FlexCell International), Frank Junker (Chief Business Officer, InSphero) and Mamun Rahman (Manager, Business Development, MBL International)
Chapter 24 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.
Chapter 25 is an appendix, that provide the list of companies and organizations mentioned in the report.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
- 3.1. Chapter Overview
- 3.2. Types of Cell Cultures
- 3.2.1. Primary Cell Cultures
- 3.2.2. Cell Lines
- 3.3. Morphology of Cells in Culture
- 3.4. 2D Cell Cultures vs 3D Cell Cultures
- 3.5. Overview of 3D Cell Culturing
- 3.5.1. Components of the Extracellular Matrix (ECM)
- 3.5.2. In Vitro Cell Culturing
- 3.5.3. Selection of Culture Format
- 3.6. Establishment and Maintenance of Cell Cultures
- 3.6.1. Isolating Cells from Tissues
- 3.6.2. Maintaining Cells in Culture
- 3.6.3. Sub-Culturing / Passaging
- 3.6.4. Cryogenic Storage
- 3.7. Requirements for Maintaining Healthy Cell Cultures
- 3.7.1. Safety Guidelines in a Cell Culture Facility
- 3.7.2. Cell Culture Health and Optimal Conditions for Growth
- 3.7.3. Cross Contamination in Cell Cultures
- 3.7.4. Methods to Prevent Contamination
- 3.8. Applications of 3D Cell Culture Systems
- 3.8.1. Model Systems
- 3.8.2. Drug Discovery and Preclinical Research
- 3.8.3. Cancer Research
- 3.8.4. Virology Research
- 3.8.5. Genetic Engineering and Gene Therapy Research
- 3.9. Advantages and Limitations of 3D Cell Culture Systems
- 3.10. Future Perspectives
4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS
- 4.1. 3D Cell Culture Classification
- 4.2. Scaffold Based 3D Cell Cultures
- 4.2.1. Hydrogels / ECM Analogs
- 4.2.2. Solid Scaffolds
- 4.2.3. Micropatterned Surfaces
- 4.2.4. Microcarriers
- 4.3. Scaffold Free 3D Cell Cultures
- 4.3.1. Attachment Resistant Surfaces
- 4.3.2. Suspension Culture Systems
- 4.3.2.1. Hanging Drop Plates
- 4.3.2.2. Magnetic Levitation and 3D Bioprinting
- 4.3.3. Microfluidic Surfaces and Organs-on-Chips
- 4.3.4. 3D Bioreactors
- 4.4. Organoids
5. FABRICATION OF 3D MATRICES AND SCAFFOLDS
- 5.1. Chapter Overview
- 5.2. Methods for Fabricating Porous Scaffolds
- 5.2.1. Particulate Leaching
- 5.2.2. Solvent Casting
- 5.2.3. Emulsion Templating
- 5.2.4. Gas Foaming
- 5.2.5. Melt Molding
- 5.2.6. Microsphere Sintering
- 5.3. Methods for Fabricating Fibrous Scaffolds
- 5.3.1. Electrospinning
- 5.3.2. Phase Separation
- 5.3.3. Self-Assembly
- 5.3.4. Fiber Mesh and Fiber Bonding
- 5.4. Methods for Fabricating Hydrogels
- 5.4.1. Gelation
- 5.4.2. Solvent Casting and Particulate Leaching
- 5.4.3. Gas Foaming
- 5.4.4. Freeze Drying
- 5.4.5. Co-polymerization / Crosslinking
- 5.4.6. Microfluidics
- 5.5. Methods for Fabricating Custom Scaffolds
- 5.5.1. Stereo-Lithography
- 5.5.2. 3D Bioprinting and Selective Laser Sintering (SLS)
- 5.5.3. Fused Deposition Modeling
- 5.5.4. Membrane Lamination
- 5.5.5. Rapid Prototyping / Solid Free-Form Technique
- 5.6. Methods for Fabricating Microspheres
- 5.6.1. Solvent Evaporation
- 5.6.2. Single and Double Emulsification
- 5.6.3. Particle Aggregation
- 5.7. Methods for Fabricating Native Scaffolds
6. 3D CELL CULTURE SYSTEMS: DEVELOPER LANDSCAPE
- 6.1. Chapter Overview
- 6.2. 3D Cell Culture System Developers: Overall Market Landscape
- 6.2.1. Analysis by Year of Establishment
- 6.2.2. Analysis by Company Size
- 6.2.3. Analysis by Location of Headquarters
- 6.2.4. Analysis by 3D Cell Culture Format
- 6.2.5. Analysis by Type of Product
- 6.2.6. Analysis by 3D Cell Culture Format and Location of Headquarters
- 6.2.7. Analysis by Company Size and Type of Product
- 6.2.8. Analysis by Location of Headquarters
- 6.3. 3D Cell Cultures: List of Service Providers
- 6.4. 3D Cell Cultures: List of Affiliated Assays, Kits and Reagents
7. MARKET LANDSCAPE: SCAFFOLD BASED PRODUCTS
- 7.1. Chapter Overview
- 7.2. Scaffold Based Products: Overall Market Landscape
- 7.2.1. Analysis by Status of Development
- 7.2.2. Analysis by Type of Product
- 7.2.3. Analysis by Source of Scaffold
- 7.2.4. Analysis by Material Used for Fabrication
- 7.2.5. Analysis by Type of Product and Source of Scaffold
- 7.2.6. Analysis by Type of Product and Material Used for Fabrication
- 7.3. Scaffold Based Products: Developer Landscape
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Company Size and Type of Product
- 7.3.4. Analysis by Location of Headquarters
- 7.3.5. Leading Developers: Analysis by Number of Scaffold Based Products
8. MARKET LANDSCAPE: SCAFFOLD FREE PRODUCTS
- 8.1. Chapter Overview
- 8.2. Scaffold Free Products: Overall Market Landscape
- 8.2.1. Analysis by Status of Development
- 8.2.2. Analysis by Type of Product
- 8.2.3. Analysis by Material Used for Fabrication
- 8.2.4. Analysis by Material Used for Scaffold
- 8.2.5. Analysis by Type of Product and Material Used for Fabrication
- 8.3. Scaffold Free Products: Developer Landscape
- 8.3.1. Analysis by Year of Establishment
- 8.3.2. Analysis by Company Size
- 8.3.3. Analysis by Company Size and Type of Product
- 8.3.4. Analysis by Location of Headquarters
- 8.3.5. Leading Developers: Analysis by Number of Scaffold Free Products
9. MARKET LANDSCAPE: 3D BIOREACTORS
- 9.1. Chapter Overview
- 9.2. 3D Bioreactors: Overall Market Landscape
- 9.2.1. Analysis by Type of 3D Bioreactor
- 9.2.2. Analysis by Status of Development
- 9.2.3. Analysis by Working Volume
- 9.2.4. Analysis by Scale of Operation
- 9.2.5. Analysis by Manufacturing Process
- 9.2.6. Analysis by Type of Cell Culture System
- 9.2.7. Analysis by Type of Molecule Processed
- 9.2.8. Analysis by Area of Application
- 9.3. 3D Bioreactors: Developer Landscape
- 9.3.1. Analysis by Year of Establishment
- 9.3.2. Analysis by Company Size
- 9.3.3. Analysis by Location of Headquarters
- 9.3.4. Leading Developers: Analysis by Number of 3D Bioreactors
10. KEY APPLICATION AREAS
- 10.1. Chapter Overview
- 10.2. 3D Cell Culture Systems in Cancer Research
- 10.2.1. Need for 3D Culture Systems in Cancer Research
- 10.2.1.1. Cancer Drug Screening with 3D Culture Systems
- 10.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
- 10.3.1. Drug Development Studies
- 10.3.2. Toxicity Screening
- 10.3.2.1. 3D Liver Models
- 10.3.2.2. Other 3D Models
- 10.4. 3D Cell Culture Systems in Stem Cell Research
- 10.4.1. 3D Culture Systems in Stem Cell Differentiation
- 10.4.2. In Vitro 3D Microenvironment to Induce Embryoid Body Formation
- 10.5. 3D Cell Cultures in Regenerative Medicine and Tissue Engineering
- 10.6. 3D Cell Culture Systems: Analysis by Key Application Areas
- 10.6.1. 3D Cell Culture Systems: Analysis by Key Application Areas and 3D Cell Culture Format
- 10.6.1.1. Scaffold Based 3D Products: Analysis by Key Application Areas
- 10.6.1.2. Scaffold Free 3D Products: Analysis by Key Application Areas
- 10.6.1.3. 3D Bioreactors: Analysis by Key Application Areas
11. COMPANY PROFILES: SCAFFOLD BASED PRODUCTS (HYDROGEL / ECM DEVELOPERS)
- 11.1. Chapter Overview
- 11.1.1. 3D Biotek
- 11.1.1.1. Company Overview
- 11.1.1.2. Product Portfolio
- 11.1.1.3. Recent Developments and Future Outlook
- 11.1.2. Advanced BioMatrix
- 11.1.2.1. Company Overview
- 11.1.2.2. Product Portfolio
- 11.1.2.3. Recent Development and Future Outlook
- 11.1.3. Alphabioregen
- 11.1.3.1. Company Overview
- 11.1.3.2. Product Portfolio
- 11.1.3.3. Recent Developments and Future Outlook
- 11.1.4. Corning Life Sciences
- 11.1.4.1. Company Overview
- 11.1.4.2. Product Portfolio
- 11.1.4.3. Recent Developments and Future Outlook
- 11.1.5. REPROCELL
- 11.1.5.1. Company Overview
- 11.1.5.2. Product Portfolio
- 11.1.5.3. Recent Developments and Future Outlook
12. COMPANY PROFILES: SCAFFOLD FREE PRODUCTS (ORGAN-ON-CHIPS DEVELOPERS)
- 12.1. Chapter Overview
- 12.1.1. CN Bio Innovations
- 12.1.1.1. Company Overview
- 12.1.1.2. Financial Information
- 12.1.1.3. Product Portfolio
- 12.1.1.4. Recent Developments and Future Outlook
- 12.1.2. Emulate
- 12.1.2.1. Company Overview
- 12.1.2.2. Financial Information
- 12.1.2.3. Product Portfolio
- 12.1.2.4. Recent Developments and Future Outlook
- 12.1.3. InSphero
- 12.1.3.1. Company Overview
- 12.1.3.2. Financial Information
- 12.1.3.3. Product Portfolio
- 12.1.3.4. Recent Developments and Future Outlook
- 12.1.4. MIMETAS
- 12.1.4.1. Company Overview
- 12.1.4.2. Financial Information
- 12.1.4.3. Product Portfolio
- 12.1.4.4. Recent Developments and Future Outlook
- 12.1.5. TissUse
- 12.1.5.1. Company Overview
- 12.1.5.2. Product Portfolio
- 12.1.5.3. Recent Developments and Future Outlook
13. COMPANY PROFILES: 3D BIOREACTORS
- 13.1. Chapter Overview
- 13.2. BISS TGT
- 13.2.1. Company Overview
- 13.2.2. Product Portfolio
- 13.2.3. Recent Developments and Future Outlook
- 13.3. Celartia
- 13.3.1. Company Overview
- 13.3.2. Product Portfolio
- 13.3.3. Recent Developments and Future Outlook
- 13.4. Cell Culture
- 13.4.1. Company Overview
- 13.4.2. Product Portfolio
- 13.4.3. Recent Developments and Future Outlook
- 13.5. EBERS
- 13.5.1. Company Overview
- 13.5.2. Product Portfolio
- 13.5.3. Recent Developments and Future Outlook
- 13.6. Flexcell International
- 13.6.1. Company Overview
- 13.6.2. Product Portfolio
- 13.6.3. Recent Developments and Future Outlook
- 13.7. PBS Biotech
- 13.7.1. Company Overview
- 13.7.2. Product Portfolio
- 13.7.3. Recent Developments and Future Outlook
- 13.8. Synthecon
- 13.8.1. Company Overview
- 13.8.2. Product Portfolio
- 13.8.3. Recent Developments and Future Outlook
14. FUNDING AND INVESTMENT ANALYSIS
- 14.1. Chapter Overview
- 14.2. Types of Funding
- 14.3. 3D Cell Culture Systems: Funding and Investment Analysis
- 14.3.1. Analysis by Number of Funding Instances
- 14.3.2. Analysis by Amount Invested
- 14.3.3. Analysis by Type of Funding
- 14.3.4. Analysis by 3D Cell Culture Format
- 14.3.5. Analysis by Type of Product
- 14.3.6. Analysis by Geography
- 14.3.7. Most Active Players: Analysis by Number of Funding Instances
- 14.3.8. Most Active Players: Analysis by Amount of Funding
- 14.3.9. Most Active Investors: Analysis by Number of Instances
- 14.4 Summary of Funding and Investments
15. PARTNERSHIPS AND COLLABORATIONS
- 15.1. Chapter Overview
- 15.2. Partnership Models
- 15.3. 3D Cell Culture Systems: List of Partnerships and Collaborations
- 15.3.1. Analysis by Year of Partnership
- 15.3.2. Analysis by Type of Partnership
- 15.3.2.1. Analysis by Year of Partnership and Type of Partnership
- 15.3.2.2. Analysis by Company Size and Type of Partnership
- 15.3.3. Analysis by Type of Partner
- 15.3.3.1. Analysis by Year of Partnership and Type of Partner
- 15.3.3.2. Analysis by Type of Partnership and Type of Partner
- 15.3.4. Analysis by 3D Cell Culture Format
- 15.3.4.1. Analysis by Year of Partnership and 3D Cell Culture Format
- 15.3.4.2. Analysis by Type of Partnership and 3D Cell Culture Format
- 15.3.5. Analysis by Type of Product
- 15.3.5.1. Analysis by Year of Partnership and Type of Product
- 15.3.5.2. Analysis by Type of Partnership and Type of Product
- 15.3.6. Most Active Players: Analysis by Number of Partnerships
- 15.3.7. Regional Analysis
- 15.3.8. Intercontinental and Intracontinental Agreements
16. PATENT ANALYSIS
- 16.1. Chapter Overview
- 16.2. Scope and Methodology
- 16.3. 3D Cell Culture Systems: Patent Analysis
- 16.3.1. Analysis by Type of Patent
- 16.3.2. Analysis by Publication Year
- 16.3.3. Analysis by Type of Patent and Publication Year
- 16.3.3. Analysis by Issuing Authority
- 16.3.4. Analysis by CPC Symbols
- 16.3.5. Analysis by Type of Applicant
- 16.3.6. Word Cloud Analysis: Emerging Focus Areas
- 16.3.7. Leading Industry Players: Analysis by Number of Patents
- 16.3.8. Leading Non-Industry Players: Analysis by Number of Patents
- 16.4. 3D Cell Culture Systems: Patent Valuation Analysis
- 16.5. Leading Patents: Analysis by Number of Citations
17. PUBLICATION ANALYSIS
- 17.1. 3D Cell Culture Systems: Publication Analysis
- 17.2. Assumptions and Key Parameters
- 17.3. Methodology
- 17.3.1. Analysis by Year of Publication
- 17.3.2. Word Cloud Analysis: Emerging Focus Areas
- 17.3.3. Top Authors: Analysis by Number of Publications
- 17.3.4. Key Journals: Analysis by Number of Publications
- 17.3.5. Key Publishers: Analysis by Number of Publications
- 17.3.6. Leading Funding Institutes: Analysis by Number of Publications
18. PRODUCT COMPETITIVENESS ANALYSIS
- 18.1. Chapter Overview
- 18.2. Assumptions / Key Parameters
- 18.3. Methodology
- 18.4. Product Competitiveness Analysis: 3D Bioreactors
- 18.4.1. Companies Headquartered in North America
- 18.4.2. Companies Headquartered in Europe
- 18.4.3. Companies Headquartered in Asia-Pacific and Rest of the World
19. CASE STUDY: ORGANIDS AND ORGAN-ON-CHIPS
- 19.1. Chapter Overview
- 19.2. Organoids and Organ-on-Chips: List of Products
- 19.2.1. Analysis by Status of Development
- 19.2.2. Analysis by Application Area
- 19.3. Organoids and Organ-on-Chips: List of Product Developers
- 19.3.1. Analysis by Year of Establishment
- 19.3.2. Analysis by Company Size
- 19.3.3. Analysis by Location of Headquarters
20. MARKET FORECAST
- 20.1. Chapter Overview
- 20.2. Key Assumptions and Forecast Methodology
- 20.3. Global 3D Cell Culture Market, 2022-2035
- 20.4. Global 3D Cell Culture Market: Distribution by Business Segment
- 20.4.1. 3D Cell Culture Systems Market, 2022-2035
- 20.4.2. 3D Cell Culture Consumables Market, 2022-2035
- 20.4.3. 3D Cell Culture Services Market, 2022-2035
- 20.5. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format
- 20.5.1. 3D Cell Culture Systems Market for Scaffold Based Products, 2022-2035
- 20.5.2. 3D Cell Culture Systems Market for Scaffold Free Products, 2022-2035
- 20.5.3. 3D Cell Culture Systems Market for 3D Bioreactors, 2022-2035
- 20.6. Global 3D Cell Culture Systems Market: Distribution by Type of Product
- 20.6.1. 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2022-2035
- 20.6.2. 3D Cell Culture Systems Market for Hydrogels / ECMs, 2022-2035
- 20.6.3 3D Cell Culture Systems Market for Micropatterned Surface, 2022-2035
- 20.6.4. 3D Cell Culture Systems Market for Microcarriers, 2022-2035
- 20.6.5. 3D Cell Culture Systems Market for Microfluidic Systems, 2022-2035
- 20.6.6. 3D Cell Culture Systems Market for Solid Scaffolds, 2022-2035
- 20.6.7. 3D Cell Culture Systems Market for Suspension Culture Systems, 2022-2035
- 20.7. Global 3D Cell Culture Systems Market: Distribution by Area of Application
- 20.7.1. 3D Cell Culture Systems Market for Cancer Research, 2022-2035
- 20.7.2 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2022-2035
- 20.7.3. 3D Cell Culture Systems Market for Stem Cell Research, 2022-2035
- 20.7.4. 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2022-2035
- 20.8. Global 3D Cell Culture Systems Market: Distribution by Purpose
- 20.8.1. 3D Cell Culture Systems Market for Research Use, 2022-2035
- 20.8.2 3D Cell Culture Systems Market for Therapeutic Use, 2022-2035
- 20.9. Global 3D Cell Culture Systems Market: Distribution by Geography
- 20.9.1. 3D Cell Culture Systems Market in North America, 2022-2035
- 20.9.2 3D Cell Culture Systems Market in Europe, 2022-2035
- 20.9.3. 3D Cell Culture Systems Market in Asia-Pacific, 2022-2035
- 20.9.4. 3D Cell Culture Systems Market in Latin America, 2022-2035
- 20.9.5. 3D Cell Culture Systems Market in Middle East and North Africa, 2022-2035
- 20.9.6. 3D Cell Culture Systems Market in Rest of the World, 2022-2035
21. SURVEY ANALYSIS
- 21.1. Chapter Overview
- 21.2. Overview of Respondents
- 21.2.1. Designation of Respondents
- 21.3. Survey Insights
- 21.3.1. 3D Cell Culture Format
- 21.3.2. Type of Product(s) Offered
- 21.3.3. Status of Development of Product(s)
- 21.3.4. Source of 3D Cultured Cells
- 21.3.5. Method Used for Fabrication
- 21.3.6. Area(s) of Application
- 21.3.7. Services Offered for 3D Cell Cultures
- 21.3.8. Current and Future Market Opportunity
22. CONCLUSION
23. EXECUTIVE INSIGHTS
- 23.1. Chapter Overview
- 23.2. Cellendes
- 23.2.1. Company Snapshot
- 23.2.2. Interview Transcript: Brigitte Angres, Co-founder
- 23.3. Synthecon
- 23.3.1. Company Snapshot
- 23.3.2. Interview Transcript: Bill Anderson, President and Chief Executive Officer
- 23.4. Anonymous
- 23.4.1. Interview Transcript: Anonymous, President and Chief Executive Officer
- 23.5. Anonymous
- 23.5.1. Interview Transcript: Anonymous, Co-founder and Vice President
- 23.6. BRTI Life Sciences
- 23.6.1. Company Snapshot
- 22.6.2. Interview Transcript: Scott Brush, Vice President
- 23.7. Kirkstall
- 23.7.1. Company Snapshot
- 23.7.2. Interview Transcript: Malcolm Wilkinson, Non-Executive Director
- 23.8. QGel
- 23.8.1. Company Snapshot
- 23.8.2. Interview Transcript: Ryder Clifford, Chief Executive Officer and Simone Carlo Rizzi, Chief Scientific Officer
- 23.9. Xylyx Bio
- 23.9.1. Company Snapshot
- 23.9.2. Interview Transcript: Tanya Yankelevich, Former Director of Product Management and Business Development
- 23.10. InSphero
- 23.10.1. Company Snapshot
- 23.10.2. Interview Transcript: Jens Kelm, Former Chief Scientific Officer
- 23.11. GSI
- 23.11.1. Company Snapshot
- 23.11.2. Interview Transcript: Walter Tinganelli, Group Leader, Clinical Radiobiology
- 23.12. Nanofiber Solutions
- 23.12.1. Company Snapshot
- 23.12.2. Interview Transcript: Darlene Thieken, Former Project Manager
- 23.13. FlexCell International
- 23.13.1. Company Snapshot
- 23.13.2. Interview Transcript: Andrea Picon, Director of Business Development
- 23.14. InSphero
- 23.14.1. Company Snapshot
- 23.14.2. Interview Transcript: Frank Junker, Chief Business officer
- 23.15. MBL International
- 23.15.1. Company Snapshot
- 23.15.2. Interview Transcript: Mamun, Rahman, Manger, Business Development
24. APPENDIX I: TABULATED DATA
25. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
- Figure 3.1 Classification of Cell Cultures
- Figure 3.2 Types of Cell Cultures
- Figure 3.3 Key Components of ECM
- Figure 3.4 Factors Influencing the Selection of 3D Cell Culture Systems
- Figure 3.5 Methods Used for Isolation of Cells from Tissues
- Figure 3.6 Methods Used for Cryogenic Storage of Cell Cultures
- Figure 3.7 Biosafety Levels for Cell Cultures
- Figure 3.8 Key Applications of Cell Cultures
- Figure 3.9 Shapes of 3D Spheroids Generated via 3D Cell Culture Systems
- Figure 3.10 Advantages and Limitations of 3D Cell Culture Systems
- Figure 4.1 Classification of 3D Cell Culture Systems
- Figure 4.2 Natural Components of ECM Used for Fabrication of Scaffolds
- Figure 4.3 Advantages and Disadvantages of Hydrogels
- Figure 4.4 Advantages of Microcarriers
- Figure 4.5 Techniques Used for Formation of 3D Spheroids
- Figure 4.6 Structures of Spinner Flask and Rotating Wall Bioreactors
- Figure 6.1 3D Cell Culture System Developers: Distribution by Year of Establishment
- Figure 6.2 3D Cell Culture System Developers: Distribution by Company Size
- Figure 6.3 3D Cell Culture System Developers: Distribution by Location of Headquarters
- Figure 6.4 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
- Figure 6.5 3D Cell Culture System Developers: Distribution by Type of Product
- Figure 6.6 Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
- Figure 6.7 Tree Map Representation: Distribution by Company Size and Type of Product
- Figure 6.8 World Map Representation: Distribution by Location of Headquarters
- Figure 7.1 Scaffold Based Products: Distribution by Status of Development
- Figure 7.2 Scaffold Based Products: Distribution by Type of Product
- Figure 7.3 Scaffold Based Products: Distribution by Source of Scaffold
- Figure 7.4 Scaffold Based Products: Distribution by Material Used for Fabrication
- Figure 7.5 Scaffold Based Products: Distribution by Type of Product and Source of Scaffold
- Figure 7.6 Scaffold Based Products: Distribution by Type of Product and Material Used for Fabrication
- Figure 7.7 Scaffold Based Product Developers: Distribution by Year of Establishment
- Figure 7.8 Scaffold Based Product Developers: Distribution by Company Size
- Figure 7.9 Scaffold Based Product Developers: Distribution by Location of Headquarters
- Figure 7.10 Leading Developers: Distribution by Number of Scaffold Based Products
- Figure 7.11 Tree Map Representation: Distribution by Company Size and Type of Product
- Figure 8.1 Scaffold Free Products: Distribution by Status of Development
- Figure 8.2 Scaffold Free Products: Distribution by Type of Product
- Figure 8.3 Scaffold Free Products: Distribution by Method Used for Fabrication
- Figure 8.4 Scaffold Free Products: Distribution by Material Used for Fabrication
- Figure 8.5 Scaffold Free Products: Distribution by Type of Product and Material Used for Fabrication
- Figure 8.6 Scaffold Free Product Developers: Distribution by Year of Establishment
- Figure 8.7 Scaffold Free Product Developers: Distribution by Company Size
- Figure 8.8 Scaffold Free Product Developers: Distribution by Location of Headquarters
- Figure 8.9 Leading Developers: Distribution by Number of Scaffold Free Products
- Figure 8.10 Tree Map Representation: Distribution by Company Size and Type of Product
- Figure 9.1 3D Bioreactors: Distribution by Type of 3D Bioreactor
- Figure 9.2 3D Bioreactors: Distribution by Status of Development
- Figure 9.3 3D Bioreactors: Distribution by Working Volume
- Figure 9.4 3D Bioreactors: Distribution by Scale of Operation
- Figure 9.5 3D Bioreactors: Distribution by Manufacturing Process
- Figure 9.6 3D Bioreactors: Distribution by Type of Cell Culture System
- Figure 9.7 3D Bioreactors: Distribution by Type of Molecule Processed
- Figure 9.8 3D Bioreactors: Distribution by Area of Application
- Figure 9.9 3D Bioreactor Developers: Distribution by Year of Establishment
- Figure 9.10 3D Bioreactor Developers: Distribution by Company Size
- Figure 9.11 3D Bioreactor Developers: Distribution by Location of Headquarters
- Figure 9.12 Leading Developers: Distribution by Number of 3D Bioreactors
- Figure 10.1 Key Application Areas of 3D Cell Culture Systems
- Figure 10.2 3D Cell Culture Systems in Cancer Research
- Figure 10.3 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
- Figure 10.4 Methods to Generate Embryoid Bodies
- Figure 10.5 Top-Down and Bottom-Up Approaches for Tissue Engineering
- Figure 10.6 3D Cell Culture Systems: Distribution by Key Application Areas
- Figure 10.7 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
- Figure 10.8 Scaffold Based 3D Products: Distribution by Key Application Areas
- Figure 10.9 Scaffold Free 3D Products: Distribution by Key Application Areas
- Figure 10.10 3D Bioreactors: Distribution by Key Application Areas
- Figure 13.1 Key Features of 3D Perfusion Bioreactors
- Figure 13.2 MagDrive and AirDrive Mechanisms for PBS Bioreactors
- Figure 13.3 Advantages of Rotary Cell Culture System (RCCS)
- Figure 14.1 Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015 - 2021
- Figure 14.2 Funding and Investments: Cumulative Number of Funding Instances by Year, 2015 - 2021
- Figure 14.3 Funding and Investments: Cumulative Amount Invested, 2015 - 2021 (USD Million)
- Figure 14.4 Funding and Investments: Distribution of Instances by Type of Funding, 2015 -2021
- Figure 14.5 Funding and Investments: Year-Wise Distribution of Instances and Type of Funding, 2015 - 2021
- Figure 14.6 Funding and Investments: Distribution by Amount Invested and Type of Funding, 2015 - 2021 (USD Million)
- Figure 14.7 Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 - 2021
- Figure 14.8 Funding and Investments: Distribution by Number of Instances and Amount Invested by 3D Cell Culture Format, 2015 - 2021
- Figure 14.9 Funding and Investments: Distribution by Number of Instances and Amount Invested by Type of Product, 2015 - 2021
- Figure 14.10 Funding and Investments: Distribution by Geography
- Figure 14.11 Funding and Investments: Regional Distribution by Total Amount Invested, 2015 - 2021
- Figure 14.12 Most Active Players: Distribution by Number of Funding Instances, 2015 -2021
- Figure 14.13 Most Active Players: Distribution by Amount Raised, 2015 - 2021 (USD Million)
- Figure 14.14 Most Active Investors: Distribution by Number of Funding Instances, 2015 -2021
- Figure 14.15 Funding and Investment Summary, 2015 - 2021 (USD Million)
- Figure 15.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015 - 2021
- Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
- Figure 15.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
- Figure 15.4 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
- Figure 15.5 Partnerships and Collaborations: Distribution by Type of Partner
- Figure 15.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
- Figure 15.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
- Figure 15.8 Partnerships and Collaborations: Distribution by 3D Cell Culture Format
- Figure 15.9 Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
- Figure 15.10 Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
- Figure 15.11 Partnerships and Collaborations: Distribution by Type of Product
- Figure 15.12 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
- Figure 15.13 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
- Figure 15.14 Most Active Players: Distribution by Number of Partnerships
- Figure 15.15 Partnerships and Collaborations: Regional Distribution
- Figure 15.16 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
- Figure 16.1 Patent Analysis: Distribution by Type of Patent
- Figure 16.2 Patent Analysis: Cumulative Distribution by Publication Year, 2016 - Q1 2022
- Figure 16.3 Patent Analysis: Distribution of Granted Patents by Publication Year, 2016 - Q1 2022
- Figure 16.4 Patent Analysis: Distribution of Filed Patents Publication Year, 2016 - Q1 2022
- Figure 16.5 Patent Analysis: Distribution by Type of Patent and Publication Year, 2016 - Q1 2022
- Figure 16.6 Patent Analysis: Distribution by Issuing Authority
- Figure 16.7 Patent Analysis: Distribution by CPC Symbols
- Figure 16.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2016 - Q1 2022
- Figure 16.9 Word Cloud Analysis: Distribution by Emerging Focus Area
- Figure 16.10 Leading Industry Players: Distribution by Number of Patents
- Figure 16.11 Leading Non-Industry Players: Distribution by Number of Patents
- Figure 16.12 Patent Analysis: Distribution by Patent Age, 2002-2022
- Figure 16.13 Patent Analysis: Distribution by Relatuve Valuation
- Figure 17.1 Publication Analysis: Distribution by Year of Publication
- Figure 17.2 Word Cloud Analysis: Emerging Focus Areas
- Figure 17.3 Top Authors: Distribution by Number of Publications
- Figure 17.4 Key Journals: Distribution by Number of Publications
- Figure 17.5 Key Publishers: Distribution by Number of Publications
- Figure 17.6 Leading Funding Institutes: Distribution by Number of Publications
- Figure 18.1 Competitiveness Analysis: 3D Bioreactors Developers based in North America
- Figure 18.2 Competitiveness Analysis: 3D Bioreactors Developers based in Europe
- Figure 18.3 Competitiveness Analysis: 3D Bioreactors Developers based in Asia-Pacific and Rest of the World
- Figure 19.1 Organoids and Organ-on-Chips: Distribution by Status of Development
- Figure 19.2 Organoids and Organ-on-Chips: Distribution by Application Area
- Figure 19.3 Organoids and Organ-on-Chips Developers: Distribution by Year of Establishment
- Figure 19.4 Organoids and Organ-on-Chips Developers: Distribution by Company Size
- Figure 19.5 Organoids and Organ-on-Chips Developers: Distribution by Location of Headquarters
- Figure 20.1 Global 3D Cell Culture Market, 2022-2035 (USD Million)
- Figure 20.2 Global 3D Cell Culture Market: Distribution by Business Segment, 2022 and 2035
- Figure 20.3 3D Cell Culture Systems Market, 2022-2035 (USD Million)
- Figure 20.4 3D Cell Culture Consumables Market, 2022-2035 (USD Million)
- Figure 20.5 3D Cell Culture Services Market, 2022-2035 (USD Million)
- Figure 20.6. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2022-2035
- Figure 20.7 3D Cell Culture Systems Market for Scaffold Based Products, 2022-2035 (USD Million)
- Figure 20.8 3D Cell Culture Systems Market for Scaffold Free Products, 2022-2035 (USD Million)
- Figure 20.9 3D Cell Culture Systems Market for 3D Bioreactors, 2022-2035 (USD Million)
- Figure 20.10 Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2022 and 2035
- Figure 20.11 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2022-2035 (USD Million)
- Figure 20.12 3D Cell Culture Systems Market for Hydrogels / ECMs, 2022-2035 (USD Million)
- Figure 20.13 3D Cell Culture Systems Market for Micropatterned Surface, 2022-2035 (USD Million)
- Figure 20.14 3D Cell Culture Systems Market for Microcarriers, 2022-2035 (USD Million)
- Figure 20.15 3D Cell Culture Systems Market for Microfluidic Systems, 2022-2035 (USD Million)
- Figure 20.16 3D Cell Culture Systems Market for Solid Scaffolds, 2022-2035 (USD Million)
- Figure 20.17 3D Cell Culture Systems Market for Suspension Cultures, 2022-2035 (USD Million)
- Figure 20.18 Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2022 and 2035
- Figure 20.19 3D Cell Culture Systems Market for Cancer Research, 2022-2035 (USD Million)
- Figure 20.20 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2022-2035 (USD Million)
- Figure 20.21 3D Cell Culture Systems Market for Stem Cell Research, 2022-2035 (USD Million)
- Figure 20.22 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2022-2035 (USD Million)
- Figure 20.23 Global 3D Cell Culture Systems Market: Distribution by Purpose, 2022 and 2035
- Figure 20.24 3D Cell Culture Systems Market for Research Use, 2022-2035 (USD Million)
- Figure 20.25 3D Cell Culture Systems Market for Therapeutic Use, 2022-2035 (USD Million)
- Figure 20.26 Global 3D Cell Culture Systems Market: Distribution by Geography, 2022 and 2035
- Figure 20.27 3D Cell Culture Systems Market in North America, 2022-2035 (USD Million)
- Figure 20.28 3D Cell Culture Systems Market in Europe, 2022-2035 (USD Million)
- Figure 20.29 3D Cell Culture Systems Market in Asia-Pacific, 2022-2035 (USD Million)
- Figure 20.30 3D Cell Culture Systems Market in Latin America, 2022-2035 (USD Million)
- Figure 20.31 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2022-2035 (USD Million)
- Figure 20.32 3D Cell Culture Systems Market in Rest of the World, 2022-2035 (USD Million)
- Figure 20.33 Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2022
- Figure 20.34 Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2022, 2028 and 2035 (USD Million)
- Figure 21.1 Survey Insights: Distribution of Respondents by Year of Establishment of the Company
- Figure 21.2 Survey Insights: Distribution of Respondents by Company Size
- Figure 21.3 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
- Figure 21.4 Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
- Figure 21.5 Survey Insights: Distribution of Respondents by Designation and Seniority Level
- Figure 21.6 Survey Insights: Distribution by Focus Area
- Figure 21.7 Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
- Figure 21.8 Survey Insights: Distribution by Status of Development of Product(s)
- Figure 21.9 Survey Insights: Distribution by Method of Fabrication Used
- Figure 21.10 Survey Insights: Distribution by Source of Cultured Cells
- Figure 21.11 Survey Insights: Distribution by Key Applications
- Figure 21.12 Survey Insights: Distribution by 3D Cell Culture Services Offered
- Figure 21.13 Survey Insights: Distribution by Current and Future Market Opportunity, 2022 and 2035
- Figure 22.1 Concluding Remarks: Overall Market Landscape of 3D Cell Culture Systems Market
- Figure 22.2 Concluding Remarks: Funding and Investments
- Figure 22.3 Concluding Remarks: Partnerships and Collaborations
- Figure 22.4 Concluding Remarks: Patent Analysis
- Figure 22.5 Concluding Remarks: Publication Analysis
- Figure 22.6 Concluding Remarks: Market Sizing and Opportunity Analysis